-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

Benzinga·09/11/2026 13:48:31
语音播报
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.